An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
ADOCIA Announces its Annual Shareholders’ Meeting to Be Held on June 28, 2022 in Paris
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Adocia has scheduled its annual shareholders’ meeting (AGM) for June 28, 2022, at 10:00 am in Paris. The notice has been published in the French Bulletin des Annonces Légales Obligatoires, detailing the agenda and proposed resolutions. Shareholders must register their shares two business days prior to the meeting to participate. They can submit questions to the Board of Directors in writing, with specific instructions provided. Adocia specializes in therapeutic solutions for diabetes and holds over 25 patent families.
Positive
Scheduled AGM demonstrates commitment to shareholder engagement.
Strong portfolio with proprietary technology platforms focused on metabolic diseases.
Negative
None.
LYON, France--(BUSINESS WIRE)--
Regulatory News:
Adocia (Paris:ADOC) (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today that it will hold its annual shareholders’ meeting (“AGM”) on June 28, 2022, at 10.00 am at Hotel de Talleyrand, in the offices of Jones Day, 2 rue Saint Florentin, 75001 Paris.
The notice of this shareholders’ meeting serving as convening notice is published today, in the French Bulletin des Annonces Légales Obligatoires (“BALO”), and includes the agenda, the proposed resolutions as well as instructions to participate and vote for this meeting.
Only shareholders having registered their shares at least two business days prior to the date of the AGM, by midnight Paris time, will be able to participate physically in the AGM. Shareholders holding bearer shares (“actions au porteur”) will need to obtain a certificate of shareholding (“attestation de participation”) from their brokers. This certificate must be attached to the proxy form or to the appropriate voting form if shareholders wish to designate a proxy or vote by post. The “attestation de participation” may replace the admission card for shareholders wishing to attend the AGM in person.
Each shareholder may submit a question in writing to the Board of Directors, this question being treated during the shareholders meeting. Questions should be sent by registered mail with return receipt to the following address: ADOCIA, 115 avenue Lacassagne - 69003 Lyon or electronic communication to the following address: ag2022@adocia.com. The written question must imperatively be accompanied by a certificate of attendance in order to be treated and must be sent no later than the fourth business day preceding the date of the general meeting.
About Adocia
Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The company has a broad portfolio of drug candidates based on three proprietary technology platforms:
1) The BioChaperone® technology for the development of new generation insulins and products combining insulins with other classes of hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation with a first application in pancreatic cells transplantation for patients with "brittle" diabetes.
Adocia holds more than 25 patent families and was ranked 4th and 7th in the French National Institute of Industrial Property (INPI) ranking of SMEs on the number of patents filed, in 2019 and 2020 respectively.
Based in Lyon, the company has approximately 115 employees. Adocia is listed on the EuronextTMParis market (Euronext: ADOC; ISIN: FR0011184241).
Disclaimer
This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those which are set forth in the “Risk Factors” section of the universal registration document that was filed with the French Autorité des marchés financiers on April 21, 2022 (a copy of which is available at www.adocia.com), in particular uncertainties that are linked to research and development, future clinical data, analyses, and the evolution of the economic context, the financial markets and the markets in which Adocia operates.
The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia as of this day. The occurrence of all or part of such risks could cause that actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements.
This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia’s shares in any jurisdiction.
